Literature DB >> 2542020

Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras.

T Crook1, J P Morgenstern, L Crawford, L Banks.   

Abstract

The close association between HPV-16 and cervical cancer implies some role for the virus in development of this cancer. Recent studies have shown that the HPV-16 E7 gene encodes the major transforming activity of the virus in baby rat kidney (BRK) cell transformation assays. To investigate the requirement for continued E7 expression in BRK cells transformed by HPV-16 E7 plus EJ-ras, we have developed a system for inducible expression of the E7 gene. The studies reported here show that continued expression of the HPV-16 E7 gene is required for maintenance of the transformed phenotype in these cells. The implications these observations bear on the role of the E7 gene in cervical carcinoma are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2542020      PMCID: PMC400835          DOI: 10.1002/j.1460-2075.1989.tb03405.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  32 in total

1.  Identification of separate domains in the adenovirus E1A gene for immortalization activity and the activation of virus early genes.

Authors:  E Moran; B Zerler; T M Harrison; M B Mathews
Journal:  Mol Cell Biol       Date:  1986-10       Impact factor: 4.272

2.  An adenovirus E1a protein region required for transformation and transcriptional repression.

Authors:  J W Lillie; M Green; M R Green
Journal:  Cell       Date:  1986-09-26       Impact factor: 41.582

3.  Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas.

Authors:  L Banks; P Spence; E Androphy; N Hubbert; G Matlashewski; A Murray; L Crawford
Journal:  J Gen Virol       Date:  1987-05       Impact factor: 3.891

4.  Bovine papillomavirus contains multiple transforming genes.

Authors:  Y C Yang; H Okayama; P M Howley
Journal:  Proc Natl Acad Sci U S A       Date:  1985-02       Impact factor: 11.205

5.  Transforming activity of human papillomavirus type 16 DNA sequence in a cervical cancer.

Authors:  Y Tsunokawa; N Takebe; T Kasamatsu; M Terada; T Sugimura
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

6.  Human papillomavirus type 16 DNA-induced malignant transformation of NIH 3T3 cells.

Authors:  S Yasumoto; A L Burkhardt; J Doniger; J A DiPaolo
Journal:  J Virol       Date:  1986-02       Impact factor: 5.103

7.  Transcription of human papillomavirus type 16 early genes in a cervical cancer and a cancer-derived cell line and identification of the E7 protein.

Authors:  D Smotkin; F O Wettstein
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

8.  Presence and expression of human papillomavirus sequences in human cervical carcinoma cell lines.

Authors:  C Yee; I Krishnan-Hewlett; C C Baker; R Schlegel; P M Howley
Journal:  Am J Pathol       Date:  1985-06       Impact factor: 4.307

9.  Transformation of human fibroblasts and keratinocytes with human papillomavirus type 16 DNA.

Authors:  L Pirisi; S Yasumoto; M Feller; J Doniger; J A DiPaolo
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

10.  Different human cervical carcinoma cell lines show similar transcription patterns of human papillomavirus type 18 early genes.

Authors:  A Schneider-Gädicke; E Schwarz
Journal:  EMBO J       Date:  1986-09       Impact factor: 11.598

View more
  57 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

Review 2.  Laboratory techniques in the investigation of human papillomavirus infection.

Authors:  E M de Villiers
Journal:  Genitourin Med       Date:  1992-02

3.  Detection of human papillomavirus type 18 E7 oncoprotein in cervical smears: a feasibility study.

Authors:  Daniela Ehehalt; Barbara Lener; Haymo Pircher; Kerstin Dreier; Heiko Pfister; Andreas M Kaufmann; Sergio Frangini; Sigrun Ressler; Elisabeth Müller-Holzner; Markus Schmitt; Daniela Höfler; Ursula Rostek; Andreas Kaiser; Andreas Widschwendter; Werner Zwerschke; Pidder Jansen-Dürr
Journal:  J Clin Microbiol       Date:  2011-11-30       Impact factor: 5.948

4.  Delineation of human papillomavirus type 18 enhancer binding proteins: the intracellular distribution of a novel octamer binding protein p92 is cell cycle regulated.

Authors:  H D Royer; M P Freyaldenhoven; I Napierski; D D Spitkovsky; T Bauknecht; N Dathan
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

5.  Metabolic analysis of senescent human fibroblasts reveals a role for AMP in cellular senescence.

Authors:  Werner Zwerschke; Sybille Mazurek; Petra Stöckl; Eveline Hütter; Erich Eigenbrodt; Pidder Jansen-Dürr
Journal:  Biochem J       Date:  2003-12-01       Impact factor: 3.857

6.  Targeted expression of the E6 and E7 oncogenes of human papillomavirus type 16 in the epidermis of transgenic mice elicits generalized epidermal hyperplasia involving autocrine factors.

Authors:  P Auewarakul; L Gissmann; A Cid-Arregui
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

7.  Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein.

Authors:  W Zwerschke; S Mazurek; P Massimi; L Banks; E Eigenbrodt; P Jansen-Dürr
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

8.  Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells.

Authors:  S Jeon; B L Allen-Hoffmann; P F Lambert
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

9.  Modulation of immortalizing properties of human papillomavirus type 16 E7 by p53 expression.

Authors:  T Crook; C Fisher; K H Vousden
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Human papillomavirus type 16 nucleoprotein E7 is a tumor rejection antigen.

Authors:  L P Chen; E K Thomas; S L Hu; I Hellström; K E Hellström
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.